<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01369888</url>
  </required_header>
  <id_info>
    <org_study_id>110170</org_study_id>
    <secondary_id>11-C-0170</secondary_id>
    <nct_id>NCT01369888</nct_id>
  </id_info>
  <brief_title>Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma</brief_title>
  <official_title>A Phase I/II Study of IL-15 Administration Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen and Autologous Lymphocyte Transfer in Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - Researchers have developed an experimental cancer treatment called cell therapy. White
      blood cells called lymphocytes are taken from a tumor, grown in large numbers in the lab, and
      then given back to the patient. Interleukin-15, given to the patient after the cells (now
      called Young tumor-infiltrating lymphocytes of Young TIL cells) are replaced, helps the cells
      to grow and boosts the immune system. This process changes your normal cells into cells that
      are able to recognize your tumor has been studied in the lab. These cells can destroy tumor
      cells in the test tube, but scientists want to see if they work inside the body.

      Objectives:

      -To test the effectiveness of lymphocytes drawn from tumor cells combined with interleukin-15
      in treating metastatic melanoma.

      Eligibility:

        -  Patients must be 18 - 66 years of age and have a diagnosis of metastatic melanoma.

        -  They will have heart and lung function tests, lab tests, and imaging procedures.

        -  Patients may not have conditions such as active systemic infections, blood clotting
           disorders, or other active major medical illnesses.

        -  Patients may not be pregnant or nursing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

        -  Tumor Infiltrating Lymphocytes (TIL) can mediate the regression of bulky metastatic
           melanoma when administered to the autologous patient along with high-dose aldesleukin
           (IL-2) following a non-myeloablative lymphodepleting chemotherapy preparative regimen.

        -  In our analysis of factors that relate to the ability of this treatment to mediate
           objective responses, we have found a highly significant inverse correlation between
           reconstitution of cluster of differentiation 4 (CD4)+ forkhead box P3 (Foxp3) + T
           regulatory cells and the likelihood of achieving an objective response.

        -  Interleukin 2 (IL-2) administration has been shown to increase the number of T
           regulatory cells and in our trials we have found a direct relationship between the
           number of IL-2 doses and the reconstitution of patients at one week with CD4+ Foxp3 + T
           regulatory cells.

        -  Interleukin 15 (IL-15) is a strong T cell growth factor, but unlike IL-2, IL-15 is not
           involved in the generation and maintenance of CD4+ Foxp3 + T regulatory cells that can
           inhibit immune reactions.

        -  In pre-clinical adoptive cell transfer studies utilizing a murine melanoma model, the
           administration of IL-15 following adoptive cell transfer improved anti-tumor effects.

      Objectives:

        -  The primary objective of this trial is to determine the safety, toxicity, and maximum
           tolerated dose of intravenous recombinant IL-15 administered as a daily intravenous
           bolus for 10 consecutive days in patients with metastatic melanoma who have received a
           lymphodepleting chemotherapy regimen and adoptive transfer of tumor infiltrating
           lymphocytes.

        -  An additional primary objective is to determine whether this combination is able to
           produce a modest number of clinical responses.

        -  The secondary objective involves the determination of the level of reconstitution of T
           regulatory cells in patients who receive cell transfer followed by IL-15 and to
           determine the pharmacokinetics of IL-15 levels in the serum following intravenous
           administration.

      Eligibility:

        -  Patients greater than or equal to 18 years old with pathologically confirmed diagnosis
           of metastatic melanoma.

        -  Patients with measurable disease, absolute neutrophil count greater than 1000/mm^3 and
           platelet count greater than 100,000/mm^3.

        -  No serious comorbid conditions such as active systemic infections, coagulation
           disorders, or other active major medical illnesses of the cardiovascular, respiratory or
           immune systems.

      Design:

        -  Patients with metastatic melanoma will undergo resection to obtain tumor for generation
           of autologous TIL cultures.

        -  Patients will receive a non-myeloablative lymphodepleting preparative regimen consisting
           of cyclophosphamide and fludarabine followed by the administration of autologous Young
           TIL. In the phase 1 portion of this study, patients will receive recombinant human IL-15
           at doses of 0.25, 0.5, 1 or 2 micrograms per kilogram give intravenously daily for 10
           days starting on the day of cell transfer. One patient will be treated at the first dose
           level, if this patient experiences a dose limiting toxicity (DLT), additional patients
           will be treated at the dose to confirm that no greater than 1/6 patients have DLT prior
           to proceeding to the next higher level. If 2 DLTs are encountered in this cohort, the
           study will be terminated. In all other cohorts, groups of three to six patients will
           receive recombinant human IL-15. Should a single patient experience a dose limiting
           toxicity due to the cell transfer at a particular dose level, additional patients will
           be treated at the dose to confirm that no greater than 1/6 patients have a DLT prior to
           proceeding to the next higher level. If a level 2 or more DLTs in 3-6 patients has been
           identified, three additional patients will be accrued at the next-lowest dose, for a
           total of 6, in order to further characterize the safety of the maximum tolerated dose
           prior to starting the phase 2 portion. In the phase 2 portion of this study, patients
           will receive a non-myeloablative lymphodepleting preparative regimen consisting of
           cyclophosphamide and fludarabine followed by the administration of autologous Young TIL
           and IL-15 at the maximum tolerated dose (MTD) established in the phase 1 portion.

        -  Studies will be performed to determine the reconstitution of patients with T regulatory
           cells and to determine the pharmacokinetics of IL-15 concentration in serum.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Closed this protocol due to autoimmune toxicity.
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Maximum Tolerated Dose (MTD) of Intravenous Recombinant IL-15 as a Daily Intravenous Bolus for 10 Consecutive Days in Patients With Metastatic Melanoma Who Have Received a Lymphodepleting Chemotherapy and ACT TIL.</measure>
    <time_frame>2 years</time_frame>
    <description>Intravenous recombinant IL-15 as a daily intravenous bolus for 10 consecutive days in patients with metastatic melanoma who have received a lymphodepleting chemotherapy and ACT TIL with dose escalation (i.e., dose level 1: 0.25 mcg, dose level 2: 0.50 mcg, dose level 3: 1 mcg, and dose level 4: 2 mcg) to further characterize the safety of the MTD prior to starting the phase 2 portion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>8 months, 9 days</time_frame>
    <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Metastatic Melanoma</condition>
  <condition>Skin Cancer</condition>
  <arm_group>
    <arm_group_label>IL-15 following Young TIL (0.25 mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25 mcg/kg/day x 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IL-15 following Young TIL (0.50 mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.50 mcg/kg/day x 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IL-15 Following Young TIL (1 mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mcg/kg/day x 10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IL-15 Following Young TIL (2 mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mcg/kg/day x 10</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>60 mg/m^2, intravenous (IV) (in the vein) x 2 days</description>
    <arm_group_label>IL-15 following Young TIL (0.25 mcg)</arm_group_label>
    <arm_group_label>IL-15 following Young TIL (0.50 mcg)</arm_group_label>
    <arm_group_label>IL-15 Following Young TIL (1 mcg)</arm_group_label>
    <arm_group_label>IL-15 Following Young TIL (2 mcg)</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)</description>
    <arm_group_label>IL-15 following Young TIL (0.25 mcg)</arm_group_label>
    <arm_group_label>IL-15 following Young TIL (0.50 mcg)</arm_group_label>
    <arm_group_label>IL-15 Following Young TIL (1 mcg)</arm_group_label>
    <arm_group_label>IL-15 Following Young TIL (2 mcg)</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tumor Infiltrating Lymphocytes</intervention_name>
    <description>IV over 30 minutes on day 0</description>
    <arm_group_label>IL-15 following Young TIL (0.25 mcg)</arm_group_label>
    <arm_group_label>IL-15 following Young TIL (0.50 mcg)</arm_group_label>
    <arm_group_label>IL-15 Following Young TIL (1 mcg)</arm_group_label>
    <arm_group_label>IL-15 Following Young TIL (2 mcg)</arm_group_label>
    <other_name>TIL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL-15</intervention_name>
    <description>IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.</description>
    <arm_group_label>IL-15 following Young TIL (0.25 mcg)</arm_group_label>
    <arm_group_label>IL-15 following Young TIL (0.50 mcg)</arm_group_label>
    <arm_group_label>IL-15 Following Young TIL (1 mcg)</arm_group_label>
    <arm_group_label>IL-15 Following Young TIL (2 mcg)</arm_group_label>
    <other_name>Interleukin 15</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Measurable metastatic melanoma with available autologous tumor infiltrating
                  lymphocyte (TIL).

               2. Patients with 3 or less brain metastases are eligible. Note: If lesions are
                  symptomatic or greater than or equal to 1 cm each, these lesions must have been
                  treated and stable for 3 months for the patient to be eligible.

               3. Greater than or equal to 18 years of age and less than or equal to age 66.

               4. Able to understand and sign the Informed Consent Document

               5. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1.

               6. Life expectancy of greater than three months.

               7. Patients of both genders must be willing to practice birth control from the time
                  of enrollment on this study and for up to four months after receiving the
                  preparative regimen.

               8. Serology:

                    1. Seronegative for human immunodeficiency virus (HIV) antibody. (The
                       experimental treatment being evaluated in this protocol depends on an intact
                       immune system. Patients who are HIV seropositive can have decreased
                       immune-competence and thus be less responsive to the experimental treatment
                       and more susceptible to its toxicities.)

                    2. Seronegative for hepatitis B antigen, and seronegative for hepatitis C
                       antibody. If hepatitis C antibody test is positive, then patient must be
                       tested for the presence of antigen by reverse transcription polymerase chain
                       reaction (RT-PCR) and be hepatitis C virus ribonucleic acid (HCV RNA)
                       negative.

                    3. Women of child-bearing potential must have a negative pregnancy test because
                       of the potentially dangerous effects of the preparative chemotherapy on the
                       fetus.

               9. Hematology:

                    1. Absolute neutrophil count greater than 1000/mm^3 without the support of
                       filgrastim.

                    2. White blood cell (WBC) (&gt; 3000/mm^3).

                    3. Platelet count greater than 100,000/mm^3.

                    4. Hemoglobin greater than 8.0 g/dl.

              10. Chemistry:

                    1. Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less
                       or equal to 2.5 times the upper limit of normal.

                    2. Serum creatinine less than or equal to 1.6 mg/dl.

                    3. Total bilirubin less than or equal to 1.5 mg/dl, except in patients with
                       Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.

              11. More than four weeks must have elapsed since any prior systemic therapy at the
                  time the patient receives the preparative regimen, and patients' toxicities must
                  have recovered to a grade 1 or less (except for toxicities such as alopecia or
                  vitiligo).

                  Note: Patients may have undergone minor surgical procedures within the past 3
                  weeks, as long as all toxicities have recovered to grade 1 or less or as
                  specified in the eligibility criteria.

              12. Six weeks must have elapsed from the time of any antibody therapy that could
                  affect an anti cancer immune response, including anti-cytotoxic T-lymphocyte
                  antigen 4 (CTLA4) antibody therapy, at the time the patient receives the
                  preparative regimen to allow antibody levels to decline.

              13. Patients who have previously received any anti-CTLA4 antibody and have documented
                  gastrointestinal (GI) toxicity must have a normal colonoscopy with normal colonic
                  biopsies.

        EXCLUSION CRITERIA:

          1. Women of child-bearing potential who are pregnant or breastfeeding because of the
             potentially dangerous effects of the treatment on the fetus or infant.

          2. Active systemic infections, coagulation disorders or other major medical illnesses of
             the cardiovascular, respiratory or immune system, myocardial infarction, cardiac
             arrhythmias, obstructive or restrictive pulmonary disease.

          3. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
             Disease).

          4. Concurrent opportunistic infections (The experimental treatment being evaluated in
             this protocol depends on an intact immune system. Patients who have decreased immune
             competence may be less responsive to the experimental treatment and more susceptible
             to its toxicities).

          5. Concurrent systemic steroid therapy.

          6. History of severe immediate hypersensitivity reaction to any of the agents used in
             this study.

          7. Any patient known to have an left ventricular ejection fraction (LVEF) less than or
             equal to 45%.

          8. In patients &gt; 60 years old, documented LVEF of less than or equal to 45%.

          9. Documented LVEF of less than or equal to 45% tested in patients with:

               1. clinically significant atrial and/or ventricular arrhythmias including but not
                  limited to: atrial fibrillation, ventricular tachycardia, second or third degree
                  heart block or.

               2. age greater than or equal to 60 years old.

         10. Documented forced expiratory volume 1 (FEV1) less than or equal to 60% predicted
             tested in patients with:

               1. A prolonged history of cigarette smoking (20 pk/year of smoking within the past 2
                  years).

               2. Symptoms of respiratory dysfunction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A Rosenberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66.</citation>
    <PMID>17237035</PMID>
  </reference>
  <reference>
    <citation>Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999 Jul;17(7):2105-16. Review.</citation>
    <PMID>10561265</PMID>
  </reference>
  <reference>
    <citation>Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer. 2007 Feb 1;109(3):455-64. Review.</citation>
    <PMID>17200963</PMID>
  </reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2011</study_first_submitted>
  <study_first_submitted_qc>June 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2011</study_first_posted>
  <results_first_submitted>January 15, 2015</results_first_submitted>
  <results_first_submitted_qc>January 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 27, 2015</results_first_posted>
  <last_update_submitted>January 26, 2015</last_update_submitted>
  <last_update_submitted_qc>January 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Steven Rosenberg, M.D.</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Cell Therapy</keyword>
  <keyword>IL-15 Cytokine</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Metastatic Melanoma</keyword>
  <keyword>Skin Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Protocol was closed due to autoimmune toxicity unlikely related to cells and probably related to the IL-15 injection seen in one pt and also due to the opening of additional surgery branch protocols suggesting pt accrual would not increase in this protocol. The maximum tolerated dose (MTD) was not determined and it did not enter the phase 2 stage.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IL-15 Following Young TIL (0.25 mcg)</title>
          <description>0.25 mcg/kg/day x 10
Cyclophosphamide: 60 mg/m^2, intravenous (IV) (in the vein) x 2 days
Fludarabine: 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
Tumor Infiltrating Lymphocytes: IV over 30 minutes on day 0
IL-15: IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.</description>
        </group>
        <group group_id="P2">
          <title>IL-15 Following Young TIL (0.50 mcg)</title>
          <description>0.50 mcg/kg/day x 10
Cyclophosphamide: 60 mg/m^2, intravenous (IV) (in the vein) x 2 days
Fludarabine: 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
Tumor Infiltrating Lymphocytes: IV over 30 minutes on day 0
IL-15: IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.</description>
        </group>
        <group group_id="P3">
          <title>IL-15 Following Young TIL (1 mcg)</title>
          <description>1 mcg/kg/day x 10
Cyclophosphamide: 60 mg/m^2, intravenous (IV) (in the vein) x 2 days
Fludarabine: 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
Tumor Infiltrating Lymphocytes: IV over 30 minutes on day 0
IL-15: IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.</description>
        </group>
        <group group_id="P4">
          <title>IL-15 Following Young TIL (2 mcg)</title>
          <description>2 mcg/kg/day x 10
Cyclophosphamide: 60 mg/m^2, intravenous (IV) (in the vein) x 2 days
Fludarabine: 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
Tumor Infiltrating Lymphocytes: IV over 30 minutes on day 0
IL-15: IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IL-15 Following Young TIL (0.25 mcg)</title>
          <description>0.25 mcg/kg/day x 10
Cyclophosphamide: 60 mg/m^2, intravenous (IV) (in the vein) x 2 days
Fludarabine: 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
Tumor Infiltrating Lymphocytes: IV over 30 minutes on day 0
IL-15: IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.</description>
        </group>
        <group group_id="B2">
          <title>IL-15 Following Young TIL (0.50 mcg)</title>
          <description>0.50 mcg/kg/day x 10
Cyclophosphamide: 60 mg/m^2, intravenous (IV) (in the vein) x 2 days
Fludarabine: 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
Tumor Infiltrating Lymphocytes: IV over 30 minutes on day 0
IL-15: IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.</description>
        </group>
        <group group_id="B3">
          <title>IL-15 Following Young TIL (10.50 mcg)</title>
          <description>1 mcg/kg/day x 10
Cyclophosphamide: 60 mg/m^2, intravenous (IV) (in the vein) x 2 days
Fludarabine: 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
Tumor Infiltrating Lymphocytes: IV over 30 minutes on day 0
IL-15: IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.</description>
        </group>
        <group group_id="B4">
          <title>IL-15 Following Young TIL (2 mcg)</title>
          <description>2 mcg/kg/day x 10
Cyclophosphamide: 60 mg/m^2, intravenous (IV) (in the vein) x 2 days
Fludarabine: 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
Tumor Infiltrating Lymphocytes: IV over 30 minutes on day 0
IL-15: IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.0"/>
                    <measurement group_id="B2" value="38." spread="5.7"/>
                    <measurement group_id="B5" value="45.7" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase 1: Maximum Tolerated Dose (MTD) of Intravenous Recombinant IL-15 as a Daily Intravenous Bolus for 10 Consecutive Days in Patients With Metastatic Melanoma Who Have Received a Lymphodepleting Chemotherapy and ACT TIL.</title>
        <description>Intravenous recombinant IL-15 as a daily intravenous bolus for 10 consecutive days in patients with metastatic melanoma who have received a lymphodepleting chemotherapy and ACT TIL with dose escalation (i.e., dose level 1: 0.25 mcg, dose level 2: 0.50 mcg, dose level 3: 1 mcg, and dose level 4: 2 mcg) to further characterize the safety of the MTD prior to starting the phase 2 portion.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IL-15 Following Young TIL (0.25 mcg)</title>
            <description>0.25 mcg/kg/day x 10
Cyclophosphamide: 60 mg/m^2, intravenous (IV) (in the vein) x 2 days
Fludarabine: 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
Tumor Infiltrating Lymphocytes: IV over 30 minutes on day 0
IL-15: IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.</description>
          </group>
          <group group_id="O2">
            <title>IL-15 Following Young TIL (0.50 mcg)</title>
            <description>0.50 mcg/kg/day x 10
Cyclophosphamide: 60 mg/m^2, intravenous (IV) (in the vein) x 2 days
Fludarabine: 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
Tumor Infiltrating Lymphocytes: IV over 30 minutes on day 0
IL-15: IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Maximum Tolerated Dose (MTD) of Intravenous Recombinant IL-15 as a Daily Intravenous Bolus for 10 Consecutive Days in Patients With Metastatic Melanoma Who Have Received a Lymphodepleting Chemotherapy and ACT TIL.</title>
          <description>Intravenous recombinant IL-15 as a daily intravenous bolus for 10 consecutive days in patients with metastatic melanoma who have received a lymphodepleting chemotherapy and ACT TIL with dose escalation (i.e., dose level 1: 0.25 mcg, dose level 2: 0.50 mcg, dose level 3: 1 mcg, and dose level 4: 2 mcg) to further characterize the safety of the MTD prior to starting the phase 2 portion.</description>
          <units>mcg/kg/day</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The MTD was not determined due to the autoimmune toxicity and it did not enter the phase 2 stage.</measurement>
                    <measurement group_id="O2" value="NA">The MTD was not determined due to the autoimmune toxicity and it did not enter the phase 2 stage.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
        <time_frame>8 months, 9 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IL-15 Following Young TIL (0.25 mcg)</title>
            <description>0.25 mcg/kg/day x 10
Cyclophosphamide: 60 mg/m^2, intravenous (IV) (in the vein) x 2 days
Fludarabine: 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
Tumor Infiltrating Lymphocytes: IV over 30 minutes on day 0
IL-15: IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.</description>
          </group>
          <group group_id="O2">
            <title>IL-15 Following Young TIL (0.50 mcg)</title>
            <description>0.50 mcg/kg/day x 10
Cyclophosphamide: 60 mg/m^2, intravenous (IV) (in the vein) x 2 days
Fludarabine: 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
Tumor Infiltrating Lymphocytes: IV over 30 minutes on day 0
IL-15: IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>IL-15 Following Young TIL (0.25 mcg)</title>
          <description>0.25 mcg/kg/day x 10
Cyclophosphamide: 60 mg/m^2, intravenous (IV) (in the vein) x 2 days
Fludarabine: 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
Tumor Infiltrating Lymphocytes: IV over 30 minutes on day 0
IL-15: IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.</description>
        </group>
        <group group_id="E2">
          <title>IL-15 Following Young TIL (0.50 mcg)</title>
          <description>0.50 mcg/kg/day x 10
Cyclophosphamide: 60 mg/m^2, intravenous (IV) (in the vein) x 2 days
Fludarabine: 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
Tumor Infiltrating Lymphocytes: IV over 30 minutes on day 0
IL-15: IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis, middle ear (non-infectious)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes/flushes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis/stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>(fever of unknown origin without clinically or microbiologically documented infection) (ANC &lt;1.0 x 10e9/L, fever &gt;38.5 degrees C)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-low (hypomagnesemia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbances</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Psychosis (hallucinations/delusions)</sub_title>
                <description>Uninvited visual images when eyes closed.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Steven Rosenberg</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>301-496-4164</phone>
      <email>sar@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

